Video Library

Working Together to Find the New Standard of Care

Dr Andrey Antov values the benefits of working within an interdisciplinary team to advance cancer care and help patients.

Andrey Antov, PhD, MBA

Video Categories: 2018 AONN Midyear and Video Library

Healthcare Team’s Relationship to the Patient

Dr Andrey Antov expands on how the healthcare team can work together to provide the best possible care for their patient.

Andrey Antov, PhD, MBA

Video Categories: 2018 AONN Midyear and Video Library

Why Are Clinical Trials Important?

Dr Andrey Antov believes it’s important for patients to participate in clinical trials for a multitude of reasons, as clinical trials can benefit both the patient and the healthcare system as a whole.

Andrey Antov, PhD, MBA

Video Categories: 2018 AONN Midyear and Video Library

Who Should Consider Genetic Testing?

Dr Andrey Antov identifies situations in which people may want to consider genetic testing.

Andrey Antov, PhD, MBA

Video Categories: 2018 AONN Midyear and Video Library

Misconceptions About Genetic and Genomic Testing

Dr Andrey Antov notes that there is often confusion around genetic and genomic testing, due in part to a lack of genetic counselors, high costs, and the rate of adoption of new technologies.

Andrey Antov, PhD, MBA

Video Categories: 2018 AONN Midyear and Video Library

The Use of Next-Generation Sequencing in Treating Non-Squamous Non-Small-Cell Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse consider how next-generation sequencing (NGS) informs treatment of lung cancer patients in providing information on tumor mutational burden, microsatellite instability, unique targetable genomic signatures, as well as novel targets that may be best addressed in a clinical trial.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

How PD-L1 Biomarker Test Results Impact Clinical Management of Lung Cancer

Drs. Goeffrey Oxnard and Lauren Ritterhouse review how the results of PD-L1 testing influence the choices in first- or second-line immunotherapy or combination immunochemotherapy in patients with squamous or non-squamous non-small-cell lung cancer.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

Accurate and Reproducible Measurement of PD-1/PD-L1

Drs. Geoff Oxnard and Lauren Ritterhouse discuss PD-1/PD-L1 as a routine biomarker test run on all lung cancer biopsy specimens, as well as on other selected cancer types, and how qualitative and quantitative results are typically reported.

Geoffrey R. Oxnard, MD; Lauren L. Ritterhouse, MD, PhD

Video Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library

What the Next Generation of Cancer Biomarkers May Involve

Dr Sanjiv Agarwala predicts that the cancer biomarkers of the future may be “mobile biomarkers,” meaning measures of the tumor microenvironment or immune response that change with therapy and may be able to determine treatment efficacy.

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

How MSI and TMB Factor into Current Biomarker Testing Panels

Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”

Sanjiv S. Agarwala, MD

Video Categories: 2018 ASCO Insights, Biomarkers, and Video Library

Sign me up!